Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Laidlaw. They set a "buy" rating and a $19.00 price target on the stock.
Nuvectis Pharma, Inc. (NVCT)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
NVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCT alerts
High impacting Nuvectis Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
NVCT
News
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research MeetingGlobeNewswire
- Nuvectis Pharma to Participate in the 37th Annual Roth ConferenceGlobeNewswire
- Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy RecommendationBusiness Wire
- Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLCGlobeNewswire
- Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets [Yahoo! Finance]Yahoo! Finance
NVCT
Earnings
- 5/7/24 - Beat
NVCT
Sec Filings
- 2/25/25 - Form 10-K
- 2/25/25 - Form 8-K
- 2/11/25 - Form 4
- NVCT's page on the SEC website